Tradename | Company | Number | Date | Products |
---|---|---|---|---|
HALDOL | Johnson & Johnson | N-015921 DISCN | 1982-01-01 | 6 products, RLD |
HALDOL SOLUTAB | Johnson & Johnson | N-017079 DISCN | 1982-01-01 | 1 products |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
HALDOL | Johnson & Johnson | N-015923 DISCN | 1982-01-01 | 1 products, RLD |
HALDOL | Johnson & Johnson | N-015922 DISCN | 1982-01-01 | 1 products, RLD |
Brand Name | Status | Last Update |
---|---|---|
haldol decanoate | New Drug Application | 2025-01-30 |
haloperidol | ANDA | 2025-04-09 |
haloperidol decanoate | ANDA | 2025-02-28 |
haloperidol lactate | ANDA | 2024-12-30 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Psychomotor agitation | D011595 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Haloperidol |
INN | haloperidol |
Description | Haloperidol is a compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety. It has a role as a serotonergic antagonist, a first generation antipsychotic, a dopaminergic antagonist, an antidyskinesia agent and an antiemetic. It is a hydroxypiperidine, an organofluorine compound, an aromatic ketone, a tertiary alcohol and a member of monochlorobenzenes. |
Classification | Small molecule |
Drug class | antipsychotics (haloperidol type) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1 |
PDB | — |
CAS-ID | 52-86-8 |
RxCUI | — |
ChEMBL ID | CHEMBL54 |
ChEBI ID | 5613 |
PubChem CID | 3559 |
DrugBank | DB00502 |
UNII ID | J6292F8L3D (ChemIDplus, GSRS) |